Program
anzutresgene autoleucel
Also written as “IMA203”, “IMA203 Product” and “IMA203 product- flat dose”.
Its studies are mostly in Melanoma, Cutaneous Malignant · Neoplasms · Melanoma, led by Immatics US.
Furthest: phase 3, since Dec 11, 20243 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immatics US | 33 open or running | phase 3since Dec 11, 2024 | Sep 25, 2018 | Jan 2028phase 3 · NCT06743126 |
Also a collaborator on its studies: Moderna.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 25, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03686124 · 375 planned · United States, Germany
- Dec 11, 2024Phase 3 study in Melanoma, Cutaneous MalignantNCT06743126 · 450 planned · United States, Canada, France and more
- Apr 19, 2025Phase 1 study in MelanomaNCT06946225 · 15 planned · United States
Ahead
- Jan 2028Primary completion: phase 3 study in Melanoma, Cutaneous MalignantNCT06743126
- Dec 2028Primary completion: phase 2 study in NeoplasmsNCT03686124
- Aug 2029Primary completion: phase 1 study in MelanomaNCT06946225
TargetBeta
PRAME →read by rule
“A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), ”NCIt, by rule
Other programs on PRAME
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| PRAME mRNA Vaccine mRNA-4203rule | Immatics US | phase 1 | 1 |
| Autologous Anti-PRAME TCR-expressing T-cells OPB-201rule | outpace-bio-inc | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06946225Melanoma · United States | 1 | Recruiting | Aug 2029 | 15 |
| NCT06743126Melanoma, Cutaneous Malignant · United States, Canada, France and more | 3 | Recruiting | Jan 2028 | 450 |
| NCT03686124Neoplasms · United States, Germany | 2 | Recruiting | Dec 2028 | 375 |
How it is read
Names in the registry
- “IMA203”, 2 entries
- “IMA203 Product”, 1 entry
- “IMA203 product- flat dose”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, Cutaneous Malignant, 1 study
- Neoplasms, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.